ArticleThe Journal of infectious diseases2020
Methods of Inactivation of SARS-CoV-2 for Downstream Biological Assays.
Article in The Journal of infectious diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 160 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
160 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- SARS-CoV-2 enzyme-linked immunosorbent assays as proxies for plaque reduction neutralisation tests.Scientific reports · 2022Trial
- Development of a Direct Cell-to-PCR Lysis Buffer Using Optimized Non-Ionic Detergents for RNA-Extraction-Free RT-qPCR.Methods and protocols · 2026Article
- Review
- Multiomic analysis identifies glutaminolysis-dependent metabolic enhancement of immune memory utilised for vaccine development.Nature communications · 2026Article
- Morphology-guided deep learning for nanoparticle agglomeration diagnostic assays.Scientific reports · 2026Article
- Nanoyeast-based impedimetric biosensor with mutated single chain antigen-binding fragment anchoring for SARS-CoV-2 detection.Biomedical microdevices · 2026Article
- Experimental Evaluation of the Efficacy of Air-Sanitizing Equipment in Neutralizing Airborne SARS-CoV-2 Virus.Pathogens (Basel, Switzerland) · 2025Article
- Protocol for mpox virus inactivation in containment level 3 for safe handling of animal samples.STAR protocols · 2025Article
- Article
- Rapid discovery of monoclonal antibodies by microfluidics-enabled FACS of single pathogen-specific antibody-secreting cells.Nature biotechnology · 2025Article
- The effect of molnupiravir and nirmatrelvir on SARS-CoV-2 genome diversity in severe models of COVID-19.Microbiology spectrum · 2025Article
- Using Machine Learning and Optical Microscopy Image Analysis of Immunosensors Made on Plasmonic Substrates: Application to Detect the SARS-CoV-2 Virus.ACS sensors · 2025Article
- Considerations for Severe Acute Respiratory Syndrome Coronavirus 2 Genomic Surveillance: A Joint Consensus Recommendation of the Association for Molecular Pathology and Association of Public Health Laboratories.The Journal of molecular diagnostics : JMD · 2025Review
- Article
- Metagenomic surveillance of microbial community and antibiotic resistant genes associated with Malaysian wastewater during the COVID-19 pandemic.Current genetics · 2024Article
- Approaches for the Inactivation ofApplied biosafety : journal of the American Biological Safety Association · 2024Article
- Optimization of SARS-CoV-2 culture from clinical samples for clinical trial applications.mSphere · 2024Article
- Detectability of cytokine and chemokine using ELISA, following sample-inactivation using Triton X-100 or heat.Scientific reports · 2024Article
- Longitudinal analysis of the lung proteome reveals persistent repair months after mild to moderate COVID-19.Cell reports. Medicine · 2024Article
100 more citing papers are in PubMed but not listed here.
Corrections and comments
- Update of
Authors and funding
11 authors.
Funding
Abstract
The scientific community has responded to the coronavirus disease 2019 (COVID-19) pandemic by rapidly undertaking research to find effective strategies to reduce the burden of this disease. Encouragingly, researchers from a diverse array of fields are collectively working towards this goal. Research with infectious severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is undertaken in high-containment laboratories; however, it is often desirable to work with samples at lower-containment levels. To facilitate the transfer of infectious samples from high-containment laboratories, we have tested methods commonly used to inactivate virus and prepare the sample for additional experiments. Incubation at 80°C, a range of detergents, Trizol reagents, and UV energies were successful at inactivating a high titer of SARS-CoV-2. Methanol and paraformaldehyde incubation of infected cells also inactivated the virus. These protocols can provide a framework for in-house inactivation of SARS-CoV-2 in other laboratories, ensuring the safe use of samples in lower-containment levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.